Innovations in Schizophrenia Treatment

This chapter explores the advancements in schizophrenia treatment, focusing on the newly FDA-approved drug Cobenphy, which offers a novel mechanism by targeting acetylcholine rather than dopamine. It also discusses the historical context of antipsychotic medications, the various side effects they produce, and the implications of Cobenphy's introduction for treatment adherence. Furthermore, the chapter delves into the ongoing challenges in pharmaceutical approaches, highlighting the importance of genetic and experiential factors in addressing the complexities of schizophrenia.